Related Experiment Video
Updated: Jan 25, 2026

Plasma-Assisted Molecular Beam Epitaxy Growth of Mg3N2 and Zn3N2 Thin Films
Published on: May 11, 2019
Genetic Deficiency of Flavin-Containing Monooxygenase 3 ( Fmo3) Protects Against Thrombosis but Has Only a Minor
Diana M Shih1, Weifei Zhu2, Rebecca C Schugar2
1From the Department of Medicine/Division of Cardiology (D.M.S., Y.M., A.M., A.J.L.), University of California, Los Angeles.
Abstract:
Objective- FMO (flavin-containing monooxygenase) 3 converts bacterial-derived trimethylamine to trimethylamine N-oxide (TMAO), an independent risk factor for cardiovascular disease. We generated FMO3 knockout (FMO3KO) mouse to study its effects on plasma TMAO, lipids, glucose/insulin metabolism, thrombosis, and atherosclerosis. Approach and Results- Previous studies with an antisense oligonucleotide (ASO) knockdown strategy targeting FMO3 in LDLRKO (low-density lipoprotein receptor knockout) mice resulted in major reductions in TMAO levels and atherosclerosis, but also showed effects on plasma lipids, insulin, and glucose. Although FMO3KO mice generated via CRISPR/Cas9 technology bred onto the LDLRKO background did exhibit similar effects on TMAO levels, the effects on lipid metabolism were not as pronounced as with the ASO knockdown model. These differences could result from either off-target effects of the ASO or from a developmental adaptation to the FMO3 deficiency. To distinguish these possibilities, we treated wild-type and FMO3KO mice with control or FMO3 ASOs. FMO3-ASO treatment led to the same extent of lipid-lowering effects in the FMO3KO mice as the wild-type mice, indicating off-target effects. The levels of TMAO in LDLRKO mice fed an atherogenic diet are very low in both wild-type and FMO3KO mice, and no significant effect was observed on atherosclerosis. When FMO3KO and wild-type mice were maintained on a 0.5% choline diet, FMO3KO showed a marked reduction in both TMAO and in vivo thrombosis potential. Conclusions- FMO3KO markedly reduces systemic TMAO levels and thrombosis potential. However, the previously observed large effects of an FMO3 ASO on plasma lipid levels appear to be due partly to off-target effects.
Insights
Flavin-containing monooxygenase 3 knockout mice significantly lower trimethylamine N-oxide (TMAO) and reduce thrombosis. Antisense oligonucleotide knockdown of FMO3 showed off-target lipid-lowering effects, not seen in knockout models.
Area of Science:
- Biochemistry and Metabolism
- Cardiovascular Disease Research
- Genetics and Molecular Biology
Background:
- Flavin-containing monooxygenase 3 (FMO3) metabolizes trimethylamine (TMA) to trimethylamine N-oxide (TMAO).
- Elevated TMAO is an independent risk factor for cardiovascular disease.
- Previous studies using antisense oligonucleotide (ASO) knockdown of FMO3 in LDLRKO mice showed reduced TMAO and atherosclerosis, but also affected lipid and glucose metabolism.
Purpose of the Study:
- To investigate the effects of FMO3 knockout (FMO3KO) on TMAO, lipids, glucose/insulin metabolism, thrombosis, and atherosclerosis.
- To differentiate between developmental adaptation to FMO3 deficiency and off-target effects of FMO3 ASO.
Main Methods:
- Generation of FMO3 knockout (FMO3KO) mice on an LDLRKO background using CRISPR/Cas9 technology.
- Treatment of wild-type and FMO3KO mice with control or FMO3 ASOs.
- Analysis of plasma TMAO, lipid levels, glucose/insulin metabolism, thrombosis potential, and atherosclerosis in mice under different dietary conditions (atherogenic diet, choline diet).
Main Results:
- FMO3KO mice exhibited reduced plasma TMAO levels and in vivo thrombosis potential, particularly on a choline-supplemented diet.
- FMO3 ASO treatment caused significant lipid-lowering effects in both wild-type and FMO3KO mice, indicating off-target effects.
- FMO3KO mice on an atherogenic diet showed no significant changes in TMAO levels or atherosclerosis compared to wild-type controls.
Conclusions:
- FMO3 deficiency, achieved through genetic knockout, effectively reduces systemic TMAO levels and thrombosis potential.
- Observed lipid-lowering effects in previous FMO3 ASO studies were partly attributed to off-target effects of the ASO.
- FMO3KO mouse model provides a tool to study TMAO-related cardiovascular disease without confounding ASO off-target effects.
Related Concept Videos
Minor Losses in Pipes
Valves play a significant role in generating minor losses by obstructing or redirecting the fluid flow. When a valve is closed or partially closed, it restricts the flow...
Structure of Lipids
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
What are Lipids?
Venous Thrombosis I: Introduction
Lipid Digestion

